CS MEDICA A/S: CS MEDICA announces that their CANNANSEN®CBD Anti-Hair Loss serum has been successfully approved in the United Arab Emirates

CS MEDICA A/S (”CS MEDICA” or the ”Company”) announces today that their CANNANSEN®CBD Anti-Hair Loss serum has been successfully approved in the United Arab Emirates. The CANNANSEN®CBD Anti-Hair Loss serum has been through an approval procedure at the United Arab Emirates Health Authorities.

The approval of the CANNANSEN®CBD Anti-Hair Loss serum from the United Arab Emirates Health Authorities is of importance for the Company’s efforts to gain brand awareness globally. The approval enables CS MEDICA to market and sell the CANNANSEN®CBD Anti-Hair Loss serum in the United Arab Emirates.

The Company acknowledges the importance of approval in the United Arab Emirates, especially in Dubai as it is an important display market for the rest of the world. Therefore, having the products approved for the market in Dubai is an important step in the right direction towards creating awareness in other markets around the world.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.